Latest / Taylor Tailored / The Hidden Crisis Behind The UK’s Scientific Decline
Transcript
- 0:00Britain still has the brains, but it is losing the race to
- 0:04move fast. Britain does not have a science
- 0:06problem because it lacks genius. It has a science problem because
- 0:11too often genius has to queue. The UK can still produce world
- 0:16class research, world class universities, world class
- 0:20biotech, world class physics, world class AI talent, and world
- 0:26class life sciences. That is the uncomfortable part.
- 0:29This is not a story of a country that forgot how to think.
- 0:33It is the story of a country that still knows how to
- 0:36discover, but has become slower, more cautious, more centralized,
- 0:41and more tangled when it tries to turn discovery into power.
- 0:45The British science story is extraordinary.
- 0:48Newton, Darwin, Farraday, Maxwell, Fleming, Hodgkin,
- 0:52Turing, Crick, Hig. The double Helix, the jet
- 0:55engine, the computer age, the birth of modern evolutionary
- 0:59biology, the foundations of electromagnetism, the logic of
- 1:04code breaking, the medical revolution of antibiotics is
- 1:08significant. The UK helped build the
- 1:10intellectual architecture of the modern world.
- 1:13Yet the question now is sharper. If Britain was once one of the
- 1:17great engines of scientific civilization, why does it
- 1:21increasingly feel like other nations are moving faster?
- 1:25The answer is not one thing. It is funding regulation,
- 1:30planning, risk aversion, fragmented policy, weak scale up
- 1:33capital, regional imbalance, slow commercialization, animal
- 1:38research, uncertainty, clinical trial friction, immigration
- 1:42barriers, and a political culture that praises innovation
- 1:46while often governing against it.
- 1:47The UK still has the raw material of a science
- 1:51superpower, but raw material is not enough.
- 1:54Science becomes national strength only when a country can
- 1:58fund it, approve it, build it, test it, scale it, and sell it.
- 2:04That is where Britain continues to struggle.
- 2:06The country that helped invent the modern scientific age.
- 2:10Britain's scientific rise was not accidental.
- 2:13It had institutions. It had empire era resources.
- 2:17It had universities with deep intellectual traditions.
- 2:22It had scientific societies. It had a culture of experiment,
- 2:26invention and engineering. It had industrial pressure.
- 2:30Mines, factories, ships, railways, medicine, agriculture
- 2:34and war all created demand for practical discovery.
- 2:38British science was never just abstract brilliance.
- 2:42It was tied to national capability.
- 2:44Newton did not merely produce equations, he helped create the
- 2:49mathematical language of the physical universe.
- 2:52Faraday and Maxwell did not merely explore electricity and
- 2:55magnetism. Their work became the foundation
- 2:58of the electrical age. Fleming's penicillin discovery
- 3:02reshaped medicine. Turing's work helped break
- 3:05wartime codes and laid conceptual foundations for
- 3:09computing. British molecular biology helped
- 3:12unlock life at the genetic level.
- 3:15For generations, Britain punched far above its population weight.
- 3:20That legacy still matters. The UK remains strong in
- 3:23universities, life sciences, biomedical research, AI, quantum
- 3:28material science, and advanced engineering.
- 3:31It is not a failed science nation.
- 3:34That would be too easy and false.
- 3:36The problem is more frustrating. Britain is sufficiently good
- 3:39enough to compete, but not organized enough to dominate.
- 3:43The decline is not collapsed, it is slippage.
- 3:46The UK is not falling behind in every scientific measure.
- 3:50Public and private RND spending has risen.
- 3:54Official figures show UK government net expenditure on
- 3:58RND reached £20.4 billion in 2024, up from £18.3 billion in
- 4:062023. Business RND performed in the UK
- 4:10reached £55.6 billion in 2024, an increase of £2.4 billion on
- 4:17the previous year. That sounds positive, because it
- 4:21is. But global competition is moving
- 4:24faster. The UK Innovation Report 2026,
- 4:28drawing on OECD data, placed EU KS RND intensity at 2.68% of GDP
- 4:36in 2023. That was South Korea at 4.96%,
- 4:41Taiwan at 3.97%, the United States at 3.45%, Japan at 3.44%
- 4:49and Germany at 3.13%. That is the gap.
- 4:54Britain is not doing anything. It is doing less than the most
- 4:58serious science economies. And in science, less compounds.
- 5:02A country that invests more can fund more labs, attract more
- 5:06researchers, build more facilities, run more trials,
- 5:11absorb more failures, scale more companies, and create deeper
- 5:15technical ecosystems. Scientific advantage is not just
- 5:19about 1 breakthrough, it is about the density of attempts.
- 5:23The UK's danger is becoming a country that creates ideas, then
- 5:28watches other places industrialize them.
- 5:30The red tape problem is real. Every serious science economy
- 5:35needs rules. Nobody sensible wants unsafe
- 5:38medicine, reckless animal research, dangerous AI
- 5:42deployment, unethical trials, contaminated products or
- 5:46untested chemical exposure. But regulation can protect the
- 5:49future, or it can slow it until the future leaves.
- 5:54Britain's regulatory problem is not simply that it has rules.
- 5:58It is that its systems can become slow, fragmented and hard
- 6:03to navigate. A scientist, founder or investor
- 6:06may face separate layers of permissions, ethics reviews,
- 6:10grant processes, planning systems, public procurement
- 6:14barriers, visa costs, data access rules, university
- 6:19bureaucracy and unclear commercialization routes.
- 6:22The House of Commons Science, Innovation and Technology
- 6:26Committee has warned that simply pouring more money into the
- 6:29existing ecosystem is not enough.
- 6:32It's 2026 report said the UK is flying blind on public and
- 6:37private R&D spending, outputs and regional impact, and argued
- 6:42that better measurement is essential if policy is to
- 6:45improve. That phrase matters because it
- 6:49gets to the heart of the problem.
- 6:50A country cannot optimize what it cannot see.
- 6:54The same report pointed to complex and slow processes in
- 6:57UKRI and innovation funding bodies, saying they can deter
- 7:02those less familiar with the system.
- 7:04It also noted that UKRI had 14 different schemes for industry
- 7:08that were described as hard to navigate.
- 7:10That is precisely how a system starts selecting for bureaucracy
- 7:15rather than brilliance. The best scientist is not always
- 7:19the best form filler. The best founder is not always
- 7:22the person who knows how to decode a grant portal.
- 7:25The strongest regional company may not have the same
- 7:28institutional machinery as a Golden Triangle university spin
- 7:32out if the process rewards those who understand it more than
- 7:36those who are building the future.
- 7:38The country has designed a drag mechanism.
- 7:41Animal testing shows the dilemma perfectly.
- 7:44Animal testing is one of the clearest examples of the tension
- 7:48between ethics, regulation and competitiveness.
- 7:51The UK has long presented itself as a leader in animal welfare.
- 7:56That is not trivial. Ethical science matters.
- 8:00Public trust matters. The unnecessary use of animals
- 8:04should be reduced wherever valid alternatives exist.
- 8:07The UK banned the use of animals in cosmetics testing in 1998.
- 8:12A complete ban was later effective throughout the EU from
- 8:162013, with limited exceptions such as occupational worker
- 8:20testing. That is a legitimate moral
- 8:24achievement. But the harder question is what
- 8:27happens when UK rules become stricter than those in countries
- 8:31still willing to conduct tests abroad, or when new alternatives
- 8:35are not yet validated quickly enough for regulators to accept
- 8:38them? If Britain bans or heavily
- 8:40restricts certain testing routes, but other countries
- 8:44allow them, the testing may continue.
- 8:46It may move. That creates A brutal policy
- 8:49paradox. The UK may feel ethically
- 8:51cleaner while losing scientific activity, investment, regulatory
- 8:56influence and commercial advantage to jurisdictions with
- 8:59looser or faster systems. The animal does not necessarily
- 9:03benefit if the work relocates. The UK scientists simply loses
- 9:07control over the standard. The government's own strategy
- 9:10recognizes that animal research still has a role where reliable
- 9:14alternatives are not yet available.
- 9:17It says animal use has contributed to life saving drugs
- 9:20and treatments, but that AI, genomics, organoids and 3D cell
- 9:26systems now create a path to reducing reliance on animals.
- 9:30That is the right direction, but the execution has to be
- 9:33ruthlessly practical. If alternatives are
- 9:36scientifically stronger, validated quickly and accepted
- 9:40internationally, Britain can lead the next era of humane
- 9:45science. If policy moves faster than
- 9:47validation, it risks becoming symbolic regulation, morally
- 9:51attractive, scientifically awkward and commercially
- 9:55damaging. The smart position is not animal
- 9:58testing forever. It is not ban everything
- 10:00tomorrow. It is this replace animal
- 10:03testing wherever alternatives are reliable, accelerate
- 10:06validation, fund new models properly, and prevent the UK
- 10:11from outsourcing difficult science to countries with weaker
- 10:14welfare standards. Otherwise, Britain does not end
- 10:17animal testing, it exports it. The future is alternatives, but
- 10:22only if Britain builds them first.
- 10:24The most promising part of the UK's animal testing strategy is
- 10:29not the banned language, it is the opportunity.
- 10:32AI toxicology, Organs on chips 3 DD tissue systems, Human cell
- 10:39models. Genomics.
- 10:40New approach methodologies. Better computational prediction,
- 10:44faster screening, more human relevant biology.
- 10:48These are not just animal welfare tools.
- 10:51They could become a strategic industry.
- 10:54The government has identified targets to apply validated
- 10:57alternatives for eye irritation and skin sensitization testing
- 11:02by the end of 2026. OECD approved methods already
- 11:06exist for skin sensitization, and animal tests are only used
- 11:10where alternative methods do not provide enough data for
- 11:13confident regulatory decisions. That is where Britain should be
- 11:16aggressive, not anti science, anti delay.
- 11:19The UK should not merely restrict old methods, it should
- 11:23become the world's best place to create, validate and
- 11:27commercialize the new ones. That means regulators,
- 11:31universities, pharmaceutical companies, biotech firms and AI
- 11:35labs need to move together. Validation has to become faster.
- 11:39Acceptance has to become international.
- 11:43Procurement has to support adoption.
- 11:45Investors need confidence that alternative methods will not sit
- 11:50in regulatory limbo for years. There is a significant
- 11:54difference between banning a tool and building a better one.
- 11:58The first is politics. The second is strategy.
- 12:02Clinical trials show Britain can move faster when it wants to.
- 12:07There are signs of improvement. The UK government has been
- 12:10pushing a 150 day target for commercial clinical trial set up
- 12:15in April 2026. It said average set up time for
- 12:20commercial clinical trials had fallen to 122 days, down from
- 12:25169 the previous year. That matters because clinical
- 12:28trials are where science becomes treatment.
- 12:31A country that is slower trials becomes less attractive to
- 12:34pharmaceutical companies, less useful to patients and less
- 12:39central to global medical development.
- 12:41A country that moves faster can bring patients into research
- 12:44earlier, attract investment, improve NHS access to innovation
- 12:49and make itself a test bed for the next generation of medicine.
- 12:53This is the model Britain needs elsewhere.
- 12:57Clear target, measured performance.
- 12:59Public accountability. Faster system.
- 13:01Not deregulation for its own sake.
- 13:03Not reckless acceleration, but discipline.
- 13:06Speed. The UK does not need to choose
- 13:08between safety and velocity. The best systems design safety
- 13:13into speed. They remove duplication, clarify
- 13:16accountability, digitize approvals, and use risk based
- 13:20regulation. Bad regulation says wait because
- 13:23the process says wait. Good regulation says move faster
- 13:27where the risk is low, scrutinize harder where the risk
- 13:30is high, and never make innovators guess where they
- 13:34stand. Other nations are not waiting.
- 13:36The UK's problem is sharpened by the fact that others are not
- 13:40standing still. South Korea has built deep
- 13:43industrial scientific strength around electronics,
- 13:47semiconductors, batteries and advanced manufacturing.
- 13:51Taiwan is central to the semiconductor world.
- 13:55The United States has vast federal science spending, world
- 13:58leading universities, deep venture capital, enormous
- 14:02defence linked innovation capacity and the ability to
- 14:06scale companies at a speed Britain rarely matches.
- 14:09Germany remains stronger in industrial RND and high value
- 14:14manufacturing. China has grown its share of
- 14:17global RND dramatically. The UK Innovation Report noted
- 14:21the China's global RND share rose from 20% to 28.1% over the
- 14:27last decade, while the G7's share fell from 58% to 52%.
- 14:33This is the reality of the science race.
- 14:36Britain is not competing against sleepy bureaucracies.
- 14:40It is competing against countries that see science as
- 14:43economic power, industrial resilience, military advantage
- 14:48and geopolitical leverage. A lab is not just a lab anymore,
- 14:52it is a future factory. AI models.
- 14:56Quantum systems, gene therapies, synthetic biology, battery
- 15:00chemistry, nuclear technology, climate engineering, robotics
- 15:05and drug discovery are not side issues.
- 15:07They are the infrastructure of national strength.
- 15:10The countries that move fastest will not merely publish papers,
- 15:15they will own platforms, patents, supply chain standards
- 15:18and markets. Britain cannot live forever on
- 15:21prestige. The commercialization gap is the
- 15:23old British disease. The UK is often good at
- 15:26invention and weaker at capture. That is the historic
- 15:29frustration. The idea begins here.
- 15:32The company scales elsewhere, the profits land somewhere else,
- 15:36and the national story becomes one of missed opportunity.
- 15:39The Commons committee has highlighted weaknesses around
- 15:42commercialization, spin outs and technology transfer.
- 15:46It noted that university spin outs are important for turning
- 15:49research into economic growth, but that some institutions need
- 15:53greater flexibility. And universities may need to
- 15:56accept smaller returns on intellectual property if that
- 16:00encourages more innovation and wider economic benefit.
- 16:04That is a crucial point. If universities take too much
- 16:07equity too early, if founders face slow negotiations, if
- 16:11investors see awkward IP terms, or if academics cannot easily
- 16:15build companies, the UK weakens its own pipeline.
- 16:19A paper is not a product. A discovery is not a company.
- 16:23A prototype is not a market. Britain needs to become less
- 16:27precious about owning a large slice of a small thing and more
- 16:31serious about creating huge companies that stay higher,
- 16:35build and pay tax. In the UK, that requires patient
- 16:39capital, founder friendly universities, faster
- 16:42procurement, better lab space, simpler grant systems and a
- 16:46planning regime that does not treat every new facility as a
- 16:50suspicious object. The regional problem Too much
- 16:54science in too few places. The UK also has a geography
- 16:58problem. The Golden Triangle of Oxford,
- 17:00Cambridge and London is one of the great research zones on
- 17:04earth. It should be celebrated, not
- 17:06resented. But it cannot be the whole
- 17:09strategy. Official Business RND figures
- 17:12show London had the largest value of business RND performed
- 17:16in 2024 at £13.3 billion, followed by the East of England
- 17:22and the Southeast. That concentration creates
- 17:24strength but also imbalance. The question is not whether
- 17:28Oxford, Cambridge and London should be weakened.
- 17:31They should not. The question is whether other
- 17:34regions are being given the infrastructure, capital, skills
- 17:38and authority to build serious clusters of their own.
- 17:41The Commons committee warned that the UK has world class
- 17:45research and growing innovation clusters but still has untapped
- 17:49potential across the regions. It argued that the government
- 17:53must better monitor and support innovation LED clusters across
- 17:57the country. That is right.
- 17:59If the UK wants science LED growth, it cannot make every
- 18:03ambitious founder migrate to the same few post codes.
- 18:07Regional universities, hospitals, manufacturers,
- 18:10defense sites, energy assets and specialist industries should be
- 18:14wired into local innovation systems.
- 18:16Science Policy cannot just be a funding announcement in London,
- 18:21it has to become a place based industrial capability.
- 18:24The future of UK science depends on a political choice.
- 18:29The UK has announced major public investment.
- 18:32UKRI says the 2025 Spending Review included record public
- 18:37RND investment of £86 billion across 2026 to 27 to 2029 to 30,
- 18:45with DSIT setting out plans for a £58.5 billion budget over the
- 18:50period. That is significant, but money
- 18:52alone will not fix the system. The future of UK science depends
- 18:57on whether the government understands the difference
- 18:59between funding science and governing for science.
- 19:03Funding science means writing checks.
- 19:07Governing for science means making the country easier to
- 19:11build in. It means faster clinical trials,
- 19:14faster lab approvals, faster visa, faster procurement,
- 19:18clearer animal research rules, faster validation of
- 19:22alternatives, better university spin out terms, more serious
- 19:26regional clusters, better infrastructure, better data,
- 19:29better commercial finance, less performative caution, more
- 19:33intelligent risk. It also means accepting that not
- 19:37every innovation can be made politically.
- 19:40Risk free. Science involves failure.
- 19:44start-ups fail. Trials fail.
- 19:46Technologies disappoint. Experiments produce negative
- 19:51results. Some bets will look foolish.
- 19:53That is the price of discovery. A country that cannot tolerate
- 19:57failure cannot lead science. It can regulate science.
- 20:01It can admire science. It can publish strategies.
- 20:05About science. But it cannot lead it.
- 20:07What most people miss. The UK science debate is often
- 20:12framed as a spending argument. Spend more, become a science
- 20:17superpower, Spend less and decline.
- 20:20That is too simple. The deeper issue is conversion.
- 20:23Can Britain convert knowledge into companies?
- 20:26Can it convert companies into scale?
- 20:28Can it convert regulation into advantage?
- 20:31Can it convert animal welfare leadership into alternative
- 20:35methods leadership? Can it convert NHS data into
- 20:39medical breakthroughs without losing public trust?
- 20:42Can it convert university brilliance into national
- 20:46productivity? That is the real test.
- 20:48The UK does not need to copy America, Korea, Taiwan, Germany
- 20:52or China exactly. It cannot.
- 20:54Each has different institutions, capital markets, industrial
- 20:59bases and political systems. But Britain does need to become
- 21:03more serious. Not louder.
- 21:04Not more slogan heavy. More serious.
- 21:07A science superpower is not a country with good press releases
- 21:11about science. It is a country where talented
- 21:14people choose to stay because the system helps them move.
- 21:18The verdict? Britain can still win, but not
- 21:22at this speed. Britain is not finished.
- 21:24That matters. The UK still has elite
- 21:26universities, global research credibility, a powerful life
- 21:30sciences base, high quality regulators, deep biomedical
- 21:34assets, strong AI talent, respected legal institutions,
- 21:39and a language advantage in global science and business.
- 21:42But the countries pulling ahead are not waiting for Britain to
- 21:46tidy up its processes. They are investing, building,
- 21:49scaling, testing, manufacturing, commercializing.
- 21:53The UK's decline is not dramatic enough to create panic, which
- 21:57makes it more dangerous. It is a slow loss of relative
- 22:00advantage, a little less RND intensity than the leaders, a
- 22:04little more bureaucracy, a little less scale up capital, a
- 22:08few more founders leaving, a few more trials going elsewhere, a
- 22:12few more regional clusters are underpowered, a few more
- 22:15technologies stuck between discovery and market.
- 22:19That is how a scientific nation slips.
- 22:22Not in. One collapse in 1000 delays the
- 22:25future of UK science is still open.
- 22:28Britain can lead in AI enabled biology, humane research,
- 22:32alternatives, clinical trials, genomics, quantum clean energy,
- 22:38advanced materials and digital health.
- 22:40It can make regulation a competitive asset rather than a
- 22:44national break. It can turn ethical standards
- 22:48into exportable scientific leadership.
- 22:50But only if it stops confusing caution with seriousness.
- 22:54Science does not reward countries that merely remember
- 22:58they were great. It rewards countries that move
- 23:01like they intend to be great again.